Congratulations to Affini-T team member, Alkeiver Cannon, PhD, Scientist I, Analytical Development, on winning a Next Generation Investigator Award! She was recently recognized at the CASSS – Sharing Science Solutions 2024 Cell and Gene Therapy Products (CGTP) Symposium she attended in Rockville, MD. #cgtp2024 #celltherapy #biopharmaceuticals
Affini-T Therapeutics
Biotechnology Research
Watertown, Massachusetts 9,584 followers
Right Targets. Right Cells. Right Place. Unlocking the power of T cells against oncogenic driver mutations.
About us
Affini-T is a leading precision immunotherapy company targeting oncogenic driver mutations, beginning with KRAS and TP53, to develop potentially curative therapies for patients with solid tumors. We are advancing two distinct therapeutic modalities encompassing adoptive cellular therapies and bispecific T cell engagers, each designed to harness T cell immunity with unprecedented precision and potency against solid tumors. Our TCR-T cell therapy-enabling platforms utilize state-of-the-art engineering, synthetic biology, and gene editing capabilities to rewrite the rules of the tumor microenvironment and optimize T cell functions. Our bispecific T cell engager platform combines high throughput affinity maturation TCR discovery and biologics format constructions to target oncogenic driver mutations. Building on the world-class innovation inherent in our leadership team, founders, and technologies, we are powered to develop transformational medicines that last.
- Website
-
https://www.affinittx.com/
External link for Affini-T Therapeutics
- Industry
- Biotechnology Research
- Company size
- 51-200 employees
- Headquarters
- Watertown, Massachusetts
- Type
- Privately Held
Locations
-
Primary
Get directions
100 Forge Rd
Watertown, Massachusetts 02472, US
Employees at Affini-T Therapeutics
Updates
-
Kim Nguyen, our CTO, and Dirk Nagorsen, our CMO, presented our #clinical AFNT-211 #Tcell program and patient journey to the ElevateBio team as part of our manufacturing partnership and enjoyed a great interactive discussion. #SolidTumors #KRAS
We recently hosted the Affini-T Therapeutics team for a fireside chat and Q&A session on their strategic partnership with ElevateBio. Affini-T is leveraging BaseCamp’s proprietary LentiPeak™️️ lentiviral vector technology platform and clinical manufacturing to advance engineered TCR-T cell therapies targeting oncogenic driver mutations. Cheers to a successful event! #CellTherapy #ElevateBio
-
-
Affini-T Therapeutics reposted this
Innovative strategies for boosting R&D productivity discussed by leaders from NextPoint Therapeutics, Inc., Affini-T Therapeutics, Rallybio, Be Biopharma & Causaly
-
-
Join our CEO, Jak Knowles, and #biotech industry leaders at the Longwood Healthcare Leaders Spring MIT Conference as they dive into the latest advancements and challenges encountered in the development of life-changing therapies for #patients. Learn more about the panel and speakers here: https://bit.ly/4b0yx8T. #drugdiscovery Ivan Cheung, NextPoint Therapeutics, Inc. Martin Mackay, Rallybio Joanne Smith-Farrell, Be Biopharma Yiannis Kiachopoulos, Causaly #longwoodhealthcareleaders
-
-
Today, our CFO, Kathy Bergsteinsson, will be at the Jefferies Global Healthcare Conference in #NewYork. Connect with her to learn more about our recent #clinical progress and pipeline of #precisionimmunotherapies for #solidtumors. #TCR
-
-
Our team is on the ground at the #ASCO24 Annual Meeting in #Chicago! Check out our Phase 1 #clinical trial-in-progress poster this afternoon where we will present clinical findings from our #celltherapy targeting #KRAS G12V in #solidtumors. Details here: https://bit.ly/3wQtBFI American Society of Clinical Oncology (ASCO)
-
-
We’re heading to #Chicago for the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting. Chat with our team in Hall A during our poster presentation to learn more about our Phase 1 #ClinicalTrial targeting #KRAS G12V in #solidtumors: https://bit.ly/3wQtBFI #ASCO24
-
-
Attending #ASCO2024 next week? Connect with our team - CEO, Jak Knowles, CSO, Loïc VINCENT, and CMO, Dirk Nagorsen – to learn more about updates on our work to develop #KRAS-targeting precision #immunotherapies for patients with #solidtumors. American Society of Clinical Oncology (ASCO)
-
-
Martina Canestraro, Director, Preclinical Development, will present preclinical data from our novel #autologous TCR-T #celltherapy program targeting #KRAS G12D later today at The New York Academy of Sciences’ Frontiers in Cancer Immunotherapy 2024. Details about the symposium are here: https://lnkd.in/e7g4MrCM. #Tcells #SolidTumors #Immunotherapy
-
-
Tomorrow, join our CTO, Kim Nguyen, and other industry leaders as Women In Bio - Engage. Educate. Empower. – Greater Boston hosts the panel discussion “Biotech Workforce Development – Recruit, Revitalize, & Retain Top Talent”. Learn more about the panel here: https://lnkd.in/eXTr5KBY. Katie Jorgensen, ElevateBio; Sue Marrichi, Ultragenyx; Vaishali Shukla, PhD, Kite Pharma; and moderator, Becky Zoccola, ElevateBio.
-